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Objective
To evaluate retrospectively the long-term results of an ap-
proach consisting of performing surgery in every patient in
whom radical removal of all metastatic disease was techni-
cally feasible.
Summary Background Data
The indications for surgical resection for liver metastases from
colorectal cancer remain controversial. Several clinical risk
factors have been reported to influence survival.
Methods
Between March 1980 and December 1997, 235 patients un-
derwent hepatic resection for metastatic colorectal cancer.
Survival rates and disease-free survival as a function of clinical
and pathologic determinants were examined retrospectively
with univariate and multivariate analyses.
Results
The overall 3-, 5-, 10-, and 15-year survival rates were 51%,
38%, 26%, and 24%, respectively. The stage of the primary
tumor, lymph node metastasis, and multiple nodules were
significantly associated with a poor prognosis in both univari-
ate and multivariate analyses. Disease-free survival was signif-
icantly influenced by lymph node metastasis, a short interval
between treatment of the primary and metastatic tumors, and
a high preoperative level of carcinoembryonic antigen. The
10-year survival rate of patients with four or more nodules
(29%) was better than that of patients with two or three nod-
ules (16%), and similar to that of patients with a solitary lesion
(32%).
Conclusions
Surgical resection is useful for treating liver metastases from
colorectal cancer. Although multiple metastases significantly
impaired the prognosis, the life expectancy of patients with
four or more nodules mandates removal.
Although surgical resection is still considered the gold stan-
dard in patients with liver metastases from colorectal cancer,
its indications are limited and the resectability rate is reported
to be only 25%.1 Moreover, the factors that affect the progno-
sis remain unclear2–20 (Table 1), and these uncertain findings,
together with the recent spread of interstitial therapies,21–25
have further reduced the indications for surgical resection.
However, techniques such as preoperative portal emboliza-
tion26 and intraoperative ultrasonography,27 which have been
associated with improvements in perioperative patient man-
agement, have led to safe hepatic resections with no deaths,
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even in patients with cirrhosis,28 and have extended the pos-
sibility of liver surgery to patients with advanced metastatic
tumors.29 Therefore, two opposite trends can be recognized:
one is toward a less-invasive approach, with broader indica-
tions for more conservative therapies such as interstitial treat-
ment, and the other is a more aggressive policy that extends the
indications for surgery.
Since 1980, we have applied the same selection criteria to
candidates for liver resection, and all of the patients with
technically resectable metastases from colorectal cancer ac-
tually underwent surgery. In this study, we retrospectively
evaluated the long-term results of our series to determine
the factors that affected the prognosis, and then tried to
clarify the surgical indications.
PATIENTS AND METHODS
From 1980 to 1997, 254 patients with hepatic metastases
from colorectal cancer underwent liver resection at the
Department of Surgery, National Cancer Center, Tokyo
(1980–1990), the First Department of Surgery, Shinshu
University, Matsumoto (1990–1994), and the Department
of Hepato-Biliary-Pancreatic Surgery, University of Tokyo,
Tokyo (1994–1997). The second author (Dr. Makuuchi)
participated in all of these operations.
The selection criteria for surgery were the possibility of
an oncologically radical operation and the possibility of
preserving at least 40% of the normal hepatic parenchyma.
The total number of hepatic metastases, their unilateral or
bilateral presentation, and the existence of extrahepatic me-
tastases were not considered exclusion criteria.
In all patients, the preoperative diagnostic workup in-
cluded ultrasonography and plain and contrast-enhanced CT
to stage the liver involvement, and chest x-ray, chest CT,
barium enema, colonoscopy, and bone scintigraphy to as-
sess for extrahepatic disease. Intraoperative bimanual liver
palpation and ultrasound were also carried out in all pa-
Table 1. SIGNIFICANCE OF PROGNOSTIC FACTORS FOR PATIENT SURVIVAL
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Butler, 19862 62 10 2 1 2 2 2 2 2 2
Iwatsuki, 19863 60 0 2 2 1 1 1
Reg. Hep. Met.,
19884 859 2 1 2 1 1 2 1 1 2 2 2
Doci, 19915 100 5 2 2 1 2 2 2 1 2 2 2
Gayowski, 19946 204 0 2 2 2 2 2 2 1 1 2 2 1 1 1 1
Pedersen, 19947 66 7.6 2 2 2 2 1 2 1 1
Scheele, 19951 469 4.4 2 2 1 2 1 2 1 2 2 1 2 2
Nordlinger, 19968 1568 2.3 2 2 1 1 1 1 1 2 2 1
Wanebo, 19969 74 7 2 2 2 2 2 2 1 1
Beckurts, 199710 126 2 2 2 2 1 2 1 1
Jaeck, 199711 747 3.6 1 2 2 2 2 2 2 1
Jamison, 199712 280 4 2 2 2 2 2 1 1
Jenkins, 199713 131 3.8 2 2 2 1 2 2 1 1
Rees, 199714 150 1 2 2 1 2 2 1
Taylor, 199715 123 0 2 2 2 2 2 1
Yasui, 199716 81 2 2 1 2 2 1
Bakalakos,
199817 301 4 2 2 2 2 1 2 1
Cady, 199818 244 3.7 2 2 1 2 1 2 1
Elias, 199819 196 1.5 2 2 1 1 2
Ohlsson, 199820 111 3.6 1 1 1
Present study 235 0 2 2 1 2 2 2 2 2 1 2 2 2 2 2 1
Rate of positivity
(%) 8 0 47 14 20 33 29 43 37 23 25 55 86 33 56 100
CEA, carcinoembryonic antigen.
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tients, and all the resections were ultrasound-guided proce-
dures.
In 19 patients, resections were not considered radical
because of gross residual disease within or outside the liver;
these patients were excluded from this study. Reasons for
nonradical resection included liver involvement judged too
extensive to permit complete resection (eight patients),
presence of a metastatic pelvic peritoneal extensive implant
(three patients), presence of metastasis of Virchow’s lymph
nodes (one patient), and lung metastasis that was not resect-
able (seven patients). All of the gross disease was removed
in the remaining 235 patients.
One hundred forty-eight patients were men and 87 were
women, with a median age of 59.2 years (range 30–80).
The primary colorectal tumor was located in the cecum in
one patient, in the ascending and transverse colon in 25 and
23, respectively, in the descending colon in 11, in the
sigmoid colon in 78, and in the rectosigmoid region in 91.
In the remaining seven patients, we could not obtain this
information because the operation was performed at another
hospital. Dukes’ staging of the primary colorectal cancer
was known in 218 of the 235 patients; it consisted of Dukes’
A in 5 patients, Dukes’ B in 50, and Dukes’ C in the
remaining 163. All the primary tumors were adenocarcino-
mas. The interval between resection of the colorectal pri-
mary tumor and hepatic resection ranged from 0 (synchro-
nous resection) to 100 months (mean 11.7 months, median
6 months); synchronous resections were performed in 109
patients. Since portal vein embolization was introduced,26
eight patients underwent this procedure before hepatic re-
section to prevent postoperative liver failure resulting from
the need to remove more than 60% of the hepatic paren-
chyma in the normal liver and four or more Couinaud
segments30 in the presence of ICG15 values ranging from
10% to 20%.31
At first hepatectomy, 619 lesions were resected, with a
mean number of 2.6 lesions per patient (median 2, range
1–17). One hundred ten patients had solitary hepatic lesions,
45 had two nodules, 27 had three, and 53 had four or more.
Regarding these latter patients, 20 had 4 nodules, 11 had 5,
5 had 6, 8 had 7, 2 had 8, and 11, 12, 13, 15 and 16 lesions
were removed in 5 other patients; 17 deposits were resected
in 2 patients. These last 53 patients had a total of 338
nodules, with a mean of 6.4 per patient. The maximum
diameter of the hepatic nodules was 0.4 to 19 cm (average
4.5 cm, median 3.9). In 146 patients, the metastasis was
unilateral (62.1%), whereas 89 patients had bilateral hepatic
deposits (37.9%). Extrahepatic direct invasion was observed
in 13 patients; it consisted of overgrowth to the diaphragm
in 6, the omentum in 2, the porta hepatis in 2, the pancreas
in 1, the right adrenal gland in 1, and the inferior vena cava
in 1. Seventeen patients had associated distant extrahepatic
metastases, which were all removed: three had lung metas-
tasis, and the rest consisted of six cases of localized peri-
toneal tumor implants, six local recurrences at the site of the
primary tumor, and two rib metastases. Lymph node me-
tastases were found in six patients, and they were also
removed at the time of liver resection. Macroscopic vascular
invasion and gross bile duct invasion were found in 24
(10.2%) and 18 patients (7.6%), respectively.
In accord with Couinaud’s anatomical classification of
the liver,30 the type of resection is shown in Table 2. One
hundred seventy-one patients showed disease relapse: in 98
of them it was in the liver, and 50 underwent further liver
resections. The total number of operations was 296 for the
235 patients, with a mean number of 1.3 per patient (median
1, range 1–4): 185 patients were operated on once, 40 twice,
9 three times, and 1 patient underwent four surgical proce-
dures. Therefore, a total of 753 nodules were removed in
one or more liver resections (mean 3.2, median 2, range
1–22). A single nodule was removed in 93 patients 2 were
removed in 45, 3 in 32, 4 in 17, 5 in 15, 6 in 7, 7 in 6, 8 in
4, 9 in 2, 10 in 3, 11 in 2, 12 in 2, and 13, 15, 16, 17, 18,
20, and 22 deposits in 1 patient each. The preoperative
serum carcinoembryonic antigen (CEA) level (normal range
0–5 ng/mL) was 0.1 to 5,711 ng/mL (average 236, median
26.9).
Overall and disease-free survival analyses were per-
formed for the entire series and on patients grouped as a
function of the following factors: sex, age (younger than 60
vs. 60 or older), primary tumor site (cecum and ascending
colon, transverse colon, descending colon, sigmoid colon,
and rectum), stage (Dukes’ A and B, Dukes’ C), interval
between treatment of the primary tumor and resection of
liver metastases (,3 months, 3–24 months, $24 months),
maximum diameter of the liver lesions (,2 cm, 2–5 cm, $5
cm), their number (single, two or three, four or more) and
intrahepatic distribution (unilateral or bilateral) at the time
of the first operation, extrahepatic direct invasion, vascular
and biliary infiltration, distant and lymph node metastases,
type of liver resection (three or more segments, one or two
Table 2. TYPE OF SURGICAL
PROCEDURES
Type of Resection No. of Patients
Three or more segments 50
Left hepatectomy 16
Extended left hepatectomy 4
Right hepatectomy 18
Extended right hepatectomy 10
Segment 4, 5, and 8 resection 2
One or two segments 48
Segment 2 and 3 resection 20
Segment 5 and 8 resection 12
Segment 6 and 7 resection 10
Segment 4 resection 6
Associated wedge resection 24
Wedge resection 137
Single 71
Multiple 66
Total 235
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segments, wedge resection), tumor-free margins (,1 cm,
$1 cm), and preoperative serum CEA level (,50 ng/mL,
$50 ng/mL). For the analysis of long-term survival, we also
considered the total number of lesions resected per patient
in one or more operations (one, two or three, and four or
more). A survival analysis was carried out using the Kaplan-
Meier (product-limit) method, with the date of the hepatic
resection as a starting point. Survival curves were compared
with the log-rank test. A multivariate stepwise Cox regres-
sion analysis was performed to identify significant contrib-
utors that were independently associated with death and
disease-free survival among those factors that were found
significant on univariate analysis. P # .05 was considered
significant.
RESULTS
The mean follow-up period was 43 months (median 28,
range 1–193). There were no deaths in the first 30 days after
surgery. The overall survival rate (Fig. 1) and survival
calculated according to patient characteristics and the fea-
tures of the primary and metastatic tumors are shown in
Table 3. Gender, age, and the site of the primary tumor were
not correlated with patient survival, whereas Dukes’ C and
an interval between colonic and liver resections of 3 months
or less were significantly associated with a poor prognosis
(Fig. 2). Patients with a solitary metastasis at the time of
surgery had a better prognosis than those with multiple
hepatic deposits (Fig. 3). Conversely, no significant differ-
ences in long-term survival were found among patients with
single nodules and those with four or more lesions: both of
these groups showed better 10-year survival rates than pa-
tients with two or three metastases (Fig. 4). Table 4 shows
the features of the long-term survivors with a total of four or
more lesions resected in one or more operations.
No statistically significant differences were observed
when survival was evaluated according to the maximum
lesion diameter or when comparing patients with unilateral
and bilateral multiple nodules. The 17 patients with extra-
hepatic distant metastases at the time of the operation had a
worse survival than those without such metastases, but this
difference was not statistically significant. In particular,
patients with localized peritoneal seedings had a mean sur-
vival of 3.1 years (range 1.2–5.1). The 13 patients with
direct extrahepatic invasion did not have a significantly
worse long-term survival than the other patients. On uni-
variate analysis, the type of surgical resection did not sig-
nificantly affect the patient prognosis, whereas the presence
of lymph node metastasis at the hepatic hilum or at the
celiac trunk at the time of the hepatectomy was significantly
associated with worse patient survival. However, macro-
scopic vascular invasion and bile duct involvement were not
significantly correlated with patient survival.
In no patients were the cut liver surfaces involved by
residual tumors, and tumor-free margins were not correlated
with patient survival. Patients with a preoperative serum
CEA level of less than 50 ng/mL had a significantly better
prognosis than those with higher values (Fig. 5).
The five variables that significantly contributed to the life
expectancy on univariate analysis were analyzed by the Cox
proportional hazard model, and the results are shown in
Table 5. Lymph node metastasis, primary tumor stage, and
number of metastases were independently associated with
patient survival, whereas none of the remaining factors was
significant in a multivariate context.
Disease-free survival data were obtained for the 235
patients (see Fig. 1), and Table 6 shows disease-free sur-
vival based on patient characteristics and the features of the
primary tumor and the liver metastases. Again, Dukes’ C
primary tumors, an interval of less than 3 months between
removal of the colorectal cancer and resection of liver
Figure 1. Overall and disease-free
survival rates of 235 patients after
the first hepatic resection.
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Table 3. LONG-TERM SURVIVAL BASED ON PATIENT CHARACTERISTICS AND
FEATURES OF PRIMARY AND METASTATIC TUMORS
Factor
No. of
Patients
Overall Survival in Years (%)
Mean Survival
(SEM)
Median Survival
(SEM) P Value3 5 10 15
Overall 235 51 38 26 24 6.1 (0.4) 3.1 (0.2)
Age (years)
,60 115 52 40 33 33 6.7 (0.7) 3.2 (0.6)
$60 120 50 36 19 —* 5.2 (0.5) 3.0 (0.2)
Gender
Female 87 49 37 25 — 5.5 (0.7) 2.9 (0.3)
Male 148 52 38 27 27 6.3 (0.6) 3.1 (0.3)
Primary tumor stage
Dukes’ A-B 55 64 54 41 — 8.1 (0.9) 7.0 (2.2)
Dukes’ C 163 44 33 21 19 5.3 (0.9) 2.6 (0.2)
Unknown 17 58 29 14 — 4.6 (1.2) 3.3 (1.1)
Primary tumor site
Cecum/ascending colon 25 63 28 28 — 5.5 (1.2) 3.3 (0.1)
Transverse colon 23 42 32 32 32 5.8 (1.4) 2.8 (0.7)
Descending colon 11 62 31 — — 3.2 (0.7) 3.3 (0.5)
Sigmoid colon 78 55 48 31 — 6.8 (0.7) 4.8 (1.4)
Rectum 91 46 32 22 — 5.2 (0.6) 2.7 (0.3)
Unknown 7 71 36 — — 4.0 (1.2) 3.2 (1.3)
Interval (months)
0–3 106 41 30 22 16 5.0 (0.6) 2.3 (0.3)
4–24 90 57 44 28 — 6.5 (0.7) 4.2 (0.8)
$25 39 64 46 30 — 6.9 (1.1) 3.3 (1.8)
Number of lesions
Single 110 63 46 32 32 7.3 (0.7) 4.3 (1.1)
Multiple 125 40 30 21 — 4.9 (0.5) 2.5 (0.2)
2–3 72 37 29 16 — 4.4 (0.6) 2.3 (0.2)
$4 53 46 32 29 — 5.1 (0.7) 2.6 (0.3)
Total resected number
1 110 63 46 32 32 7.3 (0.7) 4.3 (1.1)
2–3 77 39 33 19 — 4.8 (0.7) 2.3 (0.2)
$4 65 45 30 23 — 4.7 (0.6) 2.8 (0.3)
Tumor size (cm)
#2 54 47 35 26 — 5.7 (0.8) 2.8 (0.8)
2.1–5 113 54 43 30 26 6.6 (0.7) 3.3 (0.7)
.5 68 50 33 21 — 5.3 (0.7) 3.0 (0.3)
Tumor distribution
Unilateral 40 44 29 21 — 4.5 (0.9) 2.8 (0.4)
Bilateral 85 39 31 21 — 5.0 (0.6) 2.3 (0.3)
Extrahepatic metastases
Negative 218 52 39 28 26 6.4 (0.5) 3.2 (0.3)
Positive 17 41 21 7 — 3.5 (0.7) 2.8 (0.7)
Extrahepatic invasion
Negative 222 51 39 27 25 6.2 (0.5) 3.1 (0.4)
Positive 13 54 0 — — 2.6 (0.2) 3.1 (0.5)
Lymph node metastases
Negative 229 52 39 27 25 6.2 (0.5) 3.1 (0.2)
Positive 6 — — — — 1.2 (0.2) 1.2 (0.1)
Vascular invasion
Negative 211 50 36 25 23 6.0 (0.5) 3.0 (0.2)
Positive 24 64 52 44 — 7.5 (1.4) 5.2 (1.7)
Biliary tree invasion
Negative 217 50 38 25 23 6.0 (0.5) 3.0 (0.2)
Positive 18 65 36 36 — 5.9 (1.2) 4.2 (1.0)
Type of resection
Wedge 137 47 36 26 24 6.0 (0.6) 2.7 (0.4)
1 or 2 segments 48 56 40 27 — 5.5 (0.7) 3.1 (0.8)
3 or more segments 50 57 38 24 — 5.7 (0.9) 3.3 (0.4)
Tumor-free margin
,1 cm 118 57 45 26 — 6.2 (0.6) 4.2 (0.8)
$1 cm 27 58 24 12 — 4.4 (0.9) 3.1 (0.3)
Unknown 90 41 32 27 24 5.8 (0.7) 2.5 (0.3)
Preoperative CEA level (mg/mL)
,50 130 54 43 32 — 6.7 (0.6) 3.3 (0.6)
$50 83 42 29 18 — 4.5 (0.6) 2.2 (0.4)
Unknown 22 72 40 24 24 6.8 (1.5) 4.3 (1.2)
* All patients had either died or dropped out before this time point was reached.
CEA, carcinoembryonic antigen; NS, not significant; y, years.
NS
NS
] .0006
NS] NS
NS
] .03 .04
] NS
] .003 .001
NS
] NS
] .003
.02] NS
NS
] NS
] NS
] NS
] .0001
] NS
] NS
NS
NS
] .007
NS] NS
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metastases, the presence of multiple lesions, and a high
preoperative serum CEA level were associated with a sig-
nificantly worse disease-free survival on univariate analysis.
The presence of lymph node metastasis at the hepatic hilum
showed a borderline probability value. However, on multi-
variate analysis, only an interval of less than or equal to 3
months between treatment of the colorectal cancer and liver
resection, a high preoperative serum CEA level and the
presence of lymph node metastases at the hepatic hilum
were significant independent variables (Table 7).
Table 8 shows the survival data for patients grouped
according to the presence or absence of recurrence and the
life expectancies of those with liver relapse based on
whether they underwent further liver resections. Patients
with no recurrence showed a 100% survival rate at 15 years,
and patients with liver recurrence who underwent further
hepatic resections showed significant survival benefits.
DISCUSSION
Because 20% to 30% of patients with colorectal cancer
have synchronous or metachronous liver metastases, their
management is a common and important clinical problem.
Despite Ewing’s32 theory that liver metastases and even
lung metastases from colorectal cancers can be considered
signs of limited dissemination and are therefore suitable for
treatment, the natural history of this disease has not been
clearly defined by a controlled study.33 This lack of knowl-
edge has led to the spread of alternative treatments such as
interstitial therapies21–25 and also to controversy regarding
which factors have a significant impact on patient prognosis
after surgery, and which therefore should be considered for
patient selection. In reports during the past 15 years, the
factors in Table 1 have been reported to impair the progno-
sis significantly after surgery at an average rate of 37.6%1–20
Figure 2. Survival rate according
to whether the interval between
colorectal resection and hepatec-
tomy was 3 months or less or more
than 3 months (P 5 .008).
Figure 3. Survival rate according
to whether the lesion involved a sol-
itary metastasis or multiple metas-
tases (P 5 .003).
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(mean rate of positivity shown in Table 1). Excluding fea-
tures such as the presence of lymph node metastasis at the
hepatic hilum or the celiac trunk, which has consistently
been reported to be associated with an impaired prognosis
and which should consequently be considered a definitive
sign of disseminated disease, and gender, which has never
been reported to be a significant prognostic factor, all of the
other characteristics were reported to be significant in 8% to
86% of the reports considered (rate of positivity in Table 1).
These uncertain results have contributed to the spread of
other treatments, with the result of excluding patients with
single and small nodules from surgery.21–25,34,35 This un-
certainty also makes it possible to perform surgical treat-
ment in any patient in whom it appears to be technically
feasible.
In our experience, excluding patients with the whole liver
involved or systemic disease, the routine use of ultrasound-
guided resection procedures has eliminated incomplete tu-
mor removal, which 86% of the reports consider to be
associated with a significantly worse outcome (see Table 1).
The usefulness of intraoperative ultrasound was confirmed
by the finding that the margins of the resected specimen are
infiltrated by the tumor in 16% to 18% of patients who
undergo liver resection without intraoperative ultra-
sound.36,37 Further, complete tumor clearance is probably
the main reason for the relatively high percentage (27.3%)
of patients with no relapse and 100% survival at the 15-year
follow-up.
Sixty percent of the reports state that a tumor-free margin
of less than 1 cm is a significant prognostic factor, and the
Figure 4. Survival rate according
to the number of metastases at the
first hepatectomy: one nodule ver-
sus two or three deposits (P 5
.001), one versus four or more (NS),
and two or three versus four or
more (NS).
Table 4. FEATURES OF LONG-TERM SURVIVORS (MORE THAN 5 YEARS) AMONG
PATIENTS WITH FOUR OR MORE LIVER METASTASES
Number Age Sex
Resected Lesions per Operation Total
Resected
Lesions
Survival
1st 2nd 3rd 4th Year Status
1 75 F 5 5 11 Dead
2 47 M 5 5 13 Alive
3 60 M 4 4 10.5 Alive
4 63 M 7 7 5.5 Dead
5 66 M 12 12 9.5 Alive
6 58 M 5 5 10.5 Alive
7 41 F 4 4 12 Alive
8 41 F 3 2 5 7 Dead
9 40 M 4 4 8 Alive
10 48 F 5 5 7.5 Alive
11 44 M 1 8 9 10 Alive
12 55 M 2 4 6 5 Dead
13 73 F 4 1 2 1 8 6.5 Alive
14 52 M 13 13 6 Alive
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higher percentage of patients with larger and multiple nod-
ules who do not meet this requirement is considered to be
associated with their worse outcome.14,19 However, in our
experience, this factor did not significantly affect either the
prognosis or the disease-free survival. This is consistent
with the observations of Yamamoto et al,38 who showed
that the occurrence of satellite nodules around the main
metastatic lesion is rare and therefore wedge resection is
justified, even with a tumor-free margin of less than 0.5 to
1 cm but without exposure of the tumor on the cut surface.
Indirect confirmation is given by our results: of all the
patients with complete gross tumor removal, there was no
difference in survival based on whether the resection was
anatomical or not. Three quarters of previous reports agree
that the type of resection has no significant influence on
patient survival in the case of liver metastases (see Table 1).
Tumor size has been considered an adverse factor in
prognosis after surgery, and 43% of reports examined con-
sidered it to be of significant value.1,4,5,7,8,14 In our experi-
ence, patients with lesions larger than 5 cm in diameter had
life expectancies similar to those with lesions smaller than 2
cm. This result may be related to the fact that tumor clear-
ance was achieved in all patients, whereas among the re-
ports in which tumor size was a significant prognostic
factor, larger lesions sometimes did not receive radical
treatment.14 This could also explain in part why patients
with multiple tumors have a worse outcome than those with
single metastases. We observed a significant difference in
survival when patients were grouped according to the num-
ber of lesions, even though all patients had complete tumor
clearance. Therefore, the presence of multiple liver metas-
tases seems to be by itself a poor prognostic indicator. This
point has been recognized in only 37% of the examined
reports, including our series (see Table 1), and multifocality
was not significantly associated with disease-free survival
on our multivariate analysis.
The relevance of the number of lesions to patient survival
has historically been controversial in the international surgical
community. The discussion has focused on the cutoff number
of four metastases: for some authors, this number represents
the boundary between patients with an acceptable outcome and
those with a particularly poor prognosis.6,8,15 However, some
groups have reported no significant differences in patients with
single and multiple lesions.1,2,5,7,9,11–14,16,17,19 In some of these
reports, there were fewer than four lesions per patient in those
with multinodular presentation,2 but in others the number of
patients with more than four nodules was too small to permit
a meaningful evaluation,1,5,9,13,14 or the resections were not
Figure 5. Survival rate according
to preoperative level of carcinoem-
bryonic antigen: less than 50 ng/mL
versus 50 ng/mL or more (P 5 .07).
Table 5. RELATIVE RISK OF DEATH
WITH COX PROPORTIONAL HAZARD
MODEL
Variable RR
Multivariate 95%
Confidence Limits
Lower Upper P Value
Primary tumor stage .003
Dukes’ A-B 1
Dukes’ C 2.1 1.3 3.1
Interval (months) NS
0–3 1.6
$4 1
Number of lesions .008
Single 1
Multiple 1.7 1.1 2.4
Lymph node metastases .0002
Negative 1
Positive 5.2 2.4 15.4
Preoperative CEA level NS
,50 1
$50 1.6
CEA, carcinoembryonic antigen; RR, relative risk.
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Table 6. DISEASE-FREE SURVIVAL ACCORDING TO PATIENT CHARACTERISTICS AND
FEATURES OF PRIMARY AND METASTATIC TUMORS
Factor
No. of
Patients
Disease-Free Survival in
Years (%) Mean
Survival
(SEM)
Median
Survival
(SEM) P Value3 5 10 15
Overall 235 30 26 23 23 4.7 (0.5) 1.3 (0.1)
Age (years)
,60 115 33 29 26 26 5.0 (0.7) 1.0 (0.1)
$60 120 27 22 20 — 4.0 (0.6) 1.5 (0.1)
Gender
Female 87 28 22 20 — 4.0 (0.7) 1.3 (0.2)
Male 148 31 28 25 26 5.0 (0.6) 1.2 (0.2)
Primary tumor stage
Dukes’ A-B* 55 37 37 37 — 6.3 (0.9) 2.0 (0.3)
Dukes’ C° 163 28 22 19 19 4.0 (0.5) 1.0 (0.1)
Unknown 17 23 23 23 — 3.6 (1.4) 1.3 (0.4)
Primary tumor site
Cecum/ascending colon 25 35 28 28 — 4.5 (1.2) 1.3 (0.3)
Transverse colon 23 22 22 22 22 4.3 (1.4) 1.1 (0.9)
Descending colon 11 — — — — 1.2 (0.7) 1.0 (0.2)
Sigmoid colon 78 36 30 28 — 4.9 (0.7) 1.6 (0.4)
Rectum 91 27 23 18 — 3.8 (0.6) 1.2 (0.2)
Unknown 7 — — — — 1.5 (0.4) 0.8
Interval (months)
0–3 106 22 19 19 19 3.8 (0.6) 0.8 (0.1)
4–24 90 35 28 24 — 4.7 (0.7) 1.5 (0.2)
$25 39 38 38 31 — 4.9 (0.9) 1.8 (0.2)
Number of lesions
Single 110 41 34 29 29 5.9 (0.7) 1.8 (0.3)
Multiple 125 20 18 18 — 3.4 (0.5) 0.9 (0.1)
2–3 72 19 17 17 — 3.3 (0.7) 1.0 (0.2)
$4 53 20 20 20 — 3.1 (0.7) 0.8 (0.1)
Tumor size (cm)
#2 54 25 20 17 — 3.5 (0.7) 1.0 (0.1)
2.1–5 113 33 31 29 29 5.5 (0.7) 1.5 (0.2)
.5 68 30 22 20 — 3.6 (0.7) 1.2 (0.2)
Tumor distribution
Unilateral 40 25 21 21 — 3.9 (1.1) 1.5 (0.6)
Bilateral 85 17 17 17 — 3.2 (0.6) 0.8 (0.1)
Extrahepatic metastases
Negative 218 32 27 26 26 5.0 (0.5) 1.3 (0.2)
Positive 17 7 7 — — 1.6 (0.4) 1.2 (0.5)
Extrahepatic inavsion
Negative 222 31 26 24 24 4.8 (0.5) 1.2 (0.2)
Positive 13 — — — — 1.4 (0.2) 1.5 (0.5)
Lymph node metastases
Negative 229 30 26 24 24 4.8 (0.5) 1.3 (0.2)
Positive 6 — — — — 0.7 (0.2) 0.5 (0.1)
Vascular invasion
Negative 211 28 25 22 22 4.4 (0.5) 1.1 (0.1)
Positive 24 46 38 38 38 6.2 (1.4) 2.6 (1.2)
Biliary tree invasion
Negative 217 29 25 22 22 4.5 (0.5) 1.1 (0.2)
Positive 18 39 39 39 — 5.3 (1.3) 2.3 (1.0)
Type of resection
Wedge 137 26 23 21 21 4.3 (0.6) 1.0 (0.1)
1 or 2 segments 48 33 27 27 — 4.1 (0.7) 1.6 (0.2)
3 or more segments 50 32 31 23 — 4.7 (1.1) 1.3 (0.2)
Tumor-free margin
,1 cm 118 30 24 22 — 4.3 (0.6) 1.3 (0.2)
$1 cm 27 27 27 18 — 3.5 (1.2) 1.3 (0.4)
Unknown 100 32 30 27 27 5.1 (0.8) 1.0 (0.1)
Preoperative CEA level (ng/mL)
,50 130 35 31 30 — 5.2 (0.6) 1.5 (0.2)
$50 83 20 16 11 — 2.8 (0.6) 0.8 (0.1)
Unknown 22 25 25 25 25 5.0 (2.1) 1.7 (0.2)
CEA, carcinoembryonic antigen; NS, not significant.
NS
NS
] .007
NS
] NS
NS
] .03 .02
] NS
] .0009 .005
.004
] NS
NS
] NS
] NS
] NS
] .05
] NS
] NS
NS
NS
] .002
NS
] .04
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considered radical in most of these patients.1 Therefore, if no
definitive conclusion has been made either in favor of or
against an aggressive approach in patients with more than four
lesions, a more conservative approach would appear to be
appropriate.
Some of the authors who reported no significant differ-
ence in survival between patients with single and multiple
nodules consider more than four lesions to be a contraindi-
cation for surgery.9 In our study, 22.6% of the patients had
more than four lesions, which is the highest rate published
to date, and all of these patients underwent radical resection.
Although multiple lesions were shown to affect significantly
the prognosis on both univariate and multivariate analyses,
the long-term life expectancy of patients with four or more
lesions did not significantly differ from that of patients with
single nodules; it was actually better, although not signifi-
cantly, than that of patients with two or three lesions at the
time of surgical resection (see Table 3 and Fig. 4). An
actuarial 10-year life expectancy of 29% of those with four
or more lesions is almost equivalent to that reported for the
long-term survival in series with the most favorable situa-
tions. This is a remarkable finding, because two patients
with 13 and 12 liver metastases at the time of surgery are
still alive without recurrence at 6 and almost 10 years of
follow-up after surgery (see Table 4).**
Therefore, patients with four or more lesions should
undergo liver resection if it is technically feasible. These
conclusions should be stressed, considering the poor out-
come of similar patients treated with chemotherapy, in
whom the survival rate at 2 years is 15% to 22%.39,40
With regard to unilateral or bilateral tumor distribution,
there seems to be agreement that this factor has no prog-
nostic value, although 23% of the authors examined con-
sidered it a significant indicator of poor patient surviv-
al.6,9,17 In our series, 125 patients had multiple metastases,
but no statistically significant differences were observed in
the long-term or disease-free survival of patients with uni-
lateral or bilateral presentation. This supports our approach
of removing all lesions regardless of their distribution.
Extrahepatic infiltration or metastasis does not signifi-
cantly impair the prognosis if appropriately treated with
surgery. The life expectancy of our 17 patients with extra-
hepatic disease was not significantly worse than that of the
remaining patients, and two of them are still alive at 3 and
11 years after the first treatment. These results may not be
achievable with other treatment modalities,41 confirming the
significant improvement in prognosis that can be obtained
with extensive resections. Combined liver and lung resec-
tion is widely accepted to be effective in patients with
hepatic and pulmonary metastatic lesions from colorectal
cancer.42–46 Sugarbaker et al47 reported their results with
cytoreductive surgery and intraperitoneal chemotherapy in
patients with localized peritoneal seeding. In our six patients
with localized peritoneal seeding, we observed some sur-
vival benefit. Therefore, complete removal of the gross
tumor should not be avoided in these circumstances.
Our findings and those reported by Yasui et al16 show that
if radical removal of the tumor is possible, even the pres-
Table 7. RELATIVE RISK OF DISEASE-
FREE SURVIVAL WITH COX
PROPORTIONAL HAZARD MODEL
Variable RR
Multivariate 95%
Confidence Limits
Lower Upper P Value
Primary tumor stage NS
Dukes’ A-B 1
Dukes’ C 1.7
Interval (months) .006
0–3 1.6 1.2 2.3
$4 1
Number of lesions NS
Single 1
Multiple 1.7
Lymph node metastases .003
Negative 1
Positive 2.4 1.6 10.3
Preoperative CEA level .002
,50 1
$50 1.7 1.2 2.4
CEA, carcinoembryonic antigen; RR, relative risk.
Table 8. LONG-TERM SURVIVAL ACCORDING TO PRESENCE AND
TREATMENT OF RECURRENCE
Factor
No. of
Patients
Overall Survival in Years (%) Mean
Survival
(SE)
Median
Survival
(SE) P Value3 5 10 15
Presence of recurrence ,.00001
No 64 100 100 100 100 6.2 (0.6) 5.7 (0.1)
Yes 171 36 20 6 0 3.3 (0.2) 2.3 (0.2)
Resection
No 48 2 0 — — 1.2 (0.1) 1.1 (0.1) ,.00001
Yes 50 34 30 12 — 3.2 (0.6) 1.9 (0.1)
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ence of biliary and vascular tumor infiltration should not
exclude patients from surgery. Only Gayowski et al6 men-
tioned that this finding significantly impairs outcome. The
new opportunities provided by surgical techniques involv-
ing vascular reconstruction, using autologous vein grafts48
and preoperative portal vein embolization, to improve the
functional reserve of the remnant liver29,31 permit safe and
radical resection with no significant impairment of life
expectancy or disease-free survival compared with other
patients.
Among the remaining prognostic indicators considered,
age49,50 and primary tumor site have been reported to affect the
prognosis significantly in 1 of 114 and 1 of 7 studies,8 respec-
tively. Other factors, such as primary tumor stage, disease-free
interval between treatment of the primary tumor and liver
resection, synchronicity of the liver lesions, and the preopera-
tive serum CEA level, have been reported to be significant
prognostic factors in 20% to 47% of the series examined, and
the interval between treatment of the primary tumor and liver
metastases and the preoperative serum CEA level were inde-
pendent significant variables that influenced disease-free sur-
vival. At any rate, their respective values in the presence of
treatable liver metastases should not discourage the perfor-
mance of radical hepatectomy.
Hepatectomy should also be considered for postsurgical
recurrence: we observed a significant improvement in life
expectancy in the treated patients compared with those in
whom, because of disseminated disease or patient refusal,
further resections were not carried out (see Table 8). This
policy has been widely confirmed in the literature.51–60
Despite the fear of an increased risk of death with repeated
resection, several reports and the present series have dem-
onstrated that multiple resections can be carried out safely,
with no perioperative deaths.51–53,55,58,60 Further, our expe-
rience shows that repeated resections for a multinodular
pattern, even if it occurs as recurrence, improve the patient’s
survival, with a nonnegligible incidence of long-term sur-
vivors (see Tables 3 and 4). The possibility that each met-
astatic recurrence arises from the primary tumor and that
these new metastatic foci could have the same prognostic
indicators as the first episode should support a policy anal-
ogous to that adopted for the first liver metastasis.
By adopting an oncologically aggressive policy while
taking extreme care to preserve the liver’s functional re-
serve with the aid of intraoperative ultrasound guidance and
with the possibility of inducing hypertrophy of the remnant
liver with portal vein embolization, only 3% of the overall
series of 254 patients who underwent surgery for hepatic
metastases from colorectal cancer could not undergo radical
treatment because of extensive tumor involvement of the
liver. Complete tumor removal could be achieved in 92.5%
of the patients, despite the high rate of lesions larger than 5
cm in diameter (28.9%), more than four lesions (22.6%),
bilateral deposits (37.9%), extrahepatic invasion or metas-
tasis (12.8%), and vascular or biliary infiltration (17.8%).
These last features did not significantly influence disease-
free survival on multivariate analysis, and their role in
determining liver relapse is at best uncertain, as confirmed
by their uncertain roles as prognostic indicators in this and
other reports.1–20
The adequacy of other prognostic indicators such as DNA
flow cytometry is also controversial: some recent reports
have supported its usefulness,61,62 but others have found it
to be of little value.63,64 These heterogeneous results may be
due to differences in the methods used and the heterogeneity
of DNA ploidy between primary and liver metastases.65
Because of this uncertainty, the identification of patients
who could have a lower risk of disease relapse (which in our
experience accounted for 27.3% of all patients and showed
100% actuarial survival at 15 years) becomes even more
unpredictable. Considering the safety of liver surgery,28 as
demonstrated in this series with no deaths, and its benefits in
terms of long-term survival, these results suggest that al-
most no limitations on indications for surgical treatment, if
technically feasible, are warranted.
As with all of the other reports considered here, the
present study consisted of a retrospective evaluation cover-
ing a long duration, and some biases should be expected.
Nevertheless, new techniques, such as portal vein emboli-
zation, have extended the indications for surgery, with the
inclusion of patients with more advanced disease. Thus, this
point could only have worsened the long-term results.
In conclusion, the indications for liver resection for me-
tastases from colorectal cancer are currently determined by
the technical feasibility of the treatment, and therefore es-
sentially by the experience of the surgeons. Therefore, a
specific scientific background and adequate training in he-
patic surgery, including the ability to perform intraoperative
ultrasound and portal vein embolization, are mandatory for
performing safe and effective treatment.
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